Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044303435> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2044303435 endingPage "A115" @default.
- W2044303435 startingPage "A115" @default.
- W2044303435 abstract "Extended intramammary treatment of bovine clinical mastitis (CM) results in better cure rates but should be balanced economically against higher drug costs and extra waste of saleable milk because of a longer milk discard period. This study aimed to compare licensed extended treatment with pirlimycin (5 infusions q.d.) to shorter licensed treatments with cephapirin (2 infusions b.i.d.) and hetacillin (3 infusions q.d.) in dairy cows with CM caused by gram-positive pathogens (gram+CM), accounting for approximately 28% of all bovine mastitis cases in the US. A decision tree was developed in MS Excel, considering first and recurrent CM episodes, culling and death of dairy cows with gram+CM over an entire lactation period of 305 days. The model considered costs and losses associated with CM and its treatment, culling or deaths as well as income generated from saleable milk production and sold cows. Prices and cost data were compiled from public sources (US-2010, perspective of the producer); efficacy data were derived from published studies. All input parameters were varied extensively in one-way sensitivity analyses. Per treated cow, the income from milk production over one lactation period was $3051.72 (pirlimycin), $3054.66 (cephapirin), and $3049.21 (hetacillin). Costs associated with the disease and treatment totaled to $226.78 (pirlimycin), $236.84 (cephapirin), and $238.34 (hetacillin). As such, extended treatment with pirlimycin results in a higher profit margin of $7.12 and $14.07 per treated cow and per lactation, compared to 2 to 3 infusions with cephapirin and hetacillin, respectively. Fewer deaths or culling occurred with pirlimycin. Outcomes were most sensitive to cure rates of first mastitis episodes. With US 2010 cost/price data, the economic drawbacks of extended mastitis treatment were more than offset by better efficacy with 5-day pirlimycin treatment compared to 2 to 3 infusions with cephapirin or hetacillin." @default.
- W2044303435 created "2016-06-24" @default.
- W2044303435 creator A5034823025 @default.
- W2044303435 creator A5055392088 @default.
- W2044303435 creator A5061443238 @default.
- W2044303435 creator A5069831675 @default.
- W2044303435 date "2011-05-01" @default.
- W2044303435 modified "2023-09-28" @default.
- W2044303435 title "PIN11 EVALUATION OF COSTS AND INCOME OF AN EXTENDED TREATMENT OF CLINICAL MASTITIS CAUSED BY GRAM-POSITIVE PATHOGENS IN DAIRY COWS IN THE UNITED STATES: THE CASE OF PIRLIMYCIN" @default.
- W2044303435 doi "https://doi.org/10.1016/j.jval.2011.02.643" @default.
- W2044303435 hasPublicationYear "2011" @default.
- W2044303435 type Work @default.
- W2044303435 sameAs 2044303435 @default.
- W2044303435 citedByCount "0" @default.
- W2044303435 crossrefType "journal-article" @default.
- W2044303435 hasAuthorship W2044303435A5034823025 @default.
- W2044303435 hasAuthorship W2044303435A5055392088 @default.
- W2044303435 hasAuthorship W2044303435A5061443238 @default.
- W2044303435 hasAuthorship W2044303435A5069831675 @default.
- W2044303435 hasBestOaLocation W20443034351 @default.
- W2044303435 hasConcept C140793950 @default.
- W2044303435 hasConcept C142724271 @default.
- W2044303435 hasConcept C150903083 @default.
- W2044303435 hasConcept C194775826 @default.
- W2044303435 hasConcept C2776344049 @default.
- W2044303435 hasConcept C2776659692 @default.
- W2044303435 hasConcept C2776977481 @default.
- W2044303435 hasConcept C2779234561 @default.
- W2044303435 hasConcept C42972112 @default.
- W2044303435 hasConcept C52991690 @default.
- W2044303435 hasConcept C54355233 @default.
- W2044303435 hasConcept C71924100 @default.
- W2044303435 hasConcept C86803240 @default.
- W2044303435 hasConceptScore W2044303435C140793950 @default.
- W2044303435 hasConceptScore W2044303435C142724271 @default.
- W2044303435 hasConceptScore W2044303435C150903083 @default.
- W2044303435 hasConceptScore W2044303435C194775826 @default.
- W2044303435 hasConceptScore W2044303435C2776344049 @default.
- W2044303435 hasConceptScore W2044303435C2776659692 @default.
- W2044303435 hasConceptScore W2044303435C2776977481 @default.
- W2044303435 hasConceptScore W2044303435C2779234561 @default.
- W2044303435 hasConceptScore W2044303435C42972112 @default.
- W2044303435 hasConceptScore W2044303435C52991690 @default.
- W2044303435 hasConceptScore W2044303435C54355233 @default.
- W2044303435 hasConceptScore W2044303435C71924100 @default.
- W2044303435 hasConceptScore W2044303435C86803240 @default.
- W2044303435 hasIssue "3" @default.
- W2044303435 hasLocation W20443034351 @default.
- W2044303435 hasOpenAccess W2044303435 @default.
- W2044303435 hasPrimaryLocation W20443034351 @default.
- W2044303435 hasRelatedWork W1984912326 @default.
- W2044303435 hasRelatedWork W1987333083 @default.
- W2044303435 hasRelatedWork W2062426109 @default.
- W2044303435 hasRelatedWork W2068900226 @default.
- W2044303435 hasRelatedWork W2590527866 @default.
- W2044303435 hasRelatedWork W2944004091 @default.
- W2044303435 hasRelatedWork W2985928446 @default.
- W2044303435 hasRelatedWork W2990283461 @default.
- W2044303435 hasRelatedWork W3125117954 @default.
- W2044303435 hasRelatedWork W3184706635 @default.
- W2044303435 hasVolume "14" @default.
- W2044303435 isParatext "false" @default.
- W2044303435 isRetracted "false" @default.
- W2044303435 magId "2044303435" @default.
- W2044303435 workType "article" @default.